http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101258166-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-14 |
| filingDate | 2010-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101258166-B1 |
| titleOfInvention | Pharmaceutical composition for prevention or treatment of TVF gene mutation |
| abstract | TGFBI comprising lithium It relates to a pharmaceutical composition for the prevention or treatment of genetic variation corneal dystrophy. The pharmaceutical composition of the present invention inhibits the expression of the mutant TGFBI protein, activates the autophagy pathway to selectively dissociate and remove the mutant TGFBI protein, and also regulates oxidative stress of corneal cells, thereby controlling TGFBI. It is very effective in the prevention and treatment of genetic mutation corneal dystrophy. |
| priorityDate | 2010-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 311.